Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or refractory multiple myeloma (RRMM). It has significantly improved outcomes, including overall survival (OS), and shown superiority vs standard treatment with lenalidomide plus dexamethasone and bortezomib p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Chari, Ajai, Stewart, A. Keith, Russell, Stuart D., Moreau, Philippe, Herrmann, Joerg, Banchs, Jose, Hajek, Roman, Groarke, John, Lyon, Alexander R., Batty, George N., Ro, Sunhee, Huang, Mei, Iskander, Karim S., Lenihan, Daniel
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6039655/
https://ncbi.nlm.nih.gov/pubmed/29991494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015545
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados